8-K ·Filed Apr 28, 2026
8-K context-dependent: Items 5.02
Actionable Insight • Neutral
No immediate trading implications. Monitor the annual meeting on June 17, 2026 for any unexpected proxy contest or changes to board composition.
Final — all horizons settled through T+60d ⚠ clustered
MDGL ▲ +5.00% at T+60d
NEUTRAL call ✓ call won +5.00% · α vs SPY +0.89% · entry $518.58 → $544.51
T+1d
-0.23%
call -0.23% · α -1.25%
$517.39
settled 5mo ago
T+5d
+4.08%
call +4.08% · α +0.97%
$539.73
settled 5mo ago
T+20d
-0.51%
call -0.51% · α -6.55%
$515.96
settled 4mo ago
T+60d
+5.00%
call +5.00% · α +0.89%
$544.51
settled 2mo ago
Price Chart
Loading chart...
Executive Summary
Madrigal Pharmaceuticals reclassified two directors (Julian Baker and Daniel Brennan) to Class I to balance board classes ahead of the June 17, 2026 annual meeting. This is a routine administrative change with no material impact on operations or strategy.
Key Facts
- Julian C. Baker and Daniel J. Brennan reclassified as Class I directors effective April 22, 2026.
- Reclassification balances board classes; no change in committee assignments.
- Both directors, along with James Daly, are nominated for re-election at the June 17, 2026 annual meeting.
Financial Impact
No financial impact from this board reorganization.
Risk Factors
- Risk of contested director elections if shareholders oppose nominees, though currently no indication of opposition.
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
87% bullish (23 analysts)
Investment Themes
Biotech & Drug Discovery
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-027956 |
| Document: 0001628280-26-027956-index-headers.html | 0001628280-26-027956 |
| Document: 0001628280-26-027956-index.html | 0001628280-26-027956 |
| Document: 0001628280-26-027956.txt | 0001628280-26-027956 |
9 reports for MDGL
Track record builds as more directional reports settle.
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 12, 2026 7w ago | 8-K | $536.20 $533.12 | ▼ −0.57% | ▲ +1.32% | $496.32 (−7.44%) |
Jul 30, 2026 9w ago | 8-K | $493.11 $543.69 | ▲ +10.26% | ▲ +6.29% | $496.32 (+0.65%) |
May 22, 2026 18w ago | Insider Cluster | $524.28 $520.00 | ▼ −0.82% | ▲ +1.13% | $496.32 (−5.33%) |
May 6, 2026 21w ago | 8-K | $539.73 $488.15 | ▼ −9.56% | ▼ −12.34% | $496.32 (−8.04%) |
Apr 28, 2026 22w ago | 8-K | $518.58 $515.96 | ▼ −0.51% | ▼ −6.55% | $496.32 (−4.29%) |
Apr 22, 2026 23w ago | Press Release | $529.14 $511.82 | ▼ −3.27% | ▼ −6.44% | $496.32 (−6.20%) |
Mar 19, 2026 28w ago | Press Release | $441.16 $527.11 | ▲ +19.48% | ▲ +10.16% | $496.32 (+12.50%) |
Mar 2, 2026 30w ago | Insider Cluster | $435.62 $505.34 | ▲ +16.00% | ▲ +23.94% | $496.32 (+13.93%) |
Mar 2, 2026 30w ago | Insider Cluster | $435.62 $505.34 | ▲ +16.00% | ▲ +23.94% | $496.32 (+13.93%) |
Showing 9 of 9
US Market Status
Market Open — Closes in 46m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access